Helgi van de Velde
- Oncology top 0.5%
- Hematology top 0.2%
- Molecular Biology top 2%
- Genetics top 1%
- Pathology and Forensic Medicine top 1%
- Co-authors
- Andrew CakanaPhilippe MoreauPaul G. RichardsonDixie‐Lee EsseltineMartin KropffWilliam DeraedtXavier LeleuJesús F. San Miguel
- Topics
- Multiple Myeloma Research and Treatments (124 papers)Peptidase Inhibition and Analysis (53 papers)Protein Degradation and Inhibitors (50 papers)
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United StatesFranceBelgium
In The Last Decade
Helgi van de Velde
164 papers receiving 5.3k citations
Hit Papers
Peers
Comparison fields: 5 of 110
- Oncology 3.3k
- Hematology 3.0k
- Molecular Biology 2.8k
- Genetics 814
- Pathology and Forensic Medicine 779
Countries citing papers authored by Helgi van de Velde
This map shows the geographic impact of Helgi van de Velde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helgi van de Velde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helgi van de Velde more than expected).
Fields of papers citing papers by Helgi van de Velde
This network shows the impact of papers produced by Helgi van de Velde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helgi van de Velde. The network helps show where Helgi van de Velde may publish in the future.
Co-authorship network of co-authors of Helgi van de Velde
This figure shows the co-authorship network connecting the top 25 collaborators of Helgi van de Velde. A scholar is included among the top collaborators of Helgi van de Velde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helgi van de Velde. Helgi van de Velde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 9 | |
| 4 | 5 | |
| 5 | 3 | |
| 6 | 1 | |
| 7 | 23 | |
| 8 | 2 | |
| 9 | 17 | |
| 10 | 32 | |
| 11 | 12 | |
| 12 | 39 | |
| 13 | 20 | |
| 14 | 98 | |
| 15 | 261 | |
| 16 | 150 | |
| 17 | 166 | |
| 18 | 58 | |
| 19 | 2 | |
| 20 | 10 |
About Helgi van de Velde
Helgi van de Velde is a scholar working on Hematology, Oncology and Genetics, having authored 166 papers that have together received 5.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (124 papers), Peptidase Inhibition and Analysis (53 papers) and Protein Degradation and Inhibitors (50 papers). The work is most often cited by research in Hematology (3.0k citations), Oncology (3.3k citations) and Genetics (814 citations). Helgi van de Velde has collaborated with scholars based in United States, France and Belgium. Frequent co-authors include Andrew Cakana, Philippe Moreau, Paul G. Richardson, Dixie‐Lee Esseltine, Martin Kropff, William Deraedt, Xavier Leleu, Jesús F. San Miguel, Tadeusz Robak and Jean‐Luc Harousseau. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.